Fierce Healthcare

Medtronic CoreValve® System Shows Long-Term Efficacy and Durability in Pivotal Trial

Market-Leading Transcatheter Aortic Valve Delivers Positive Clinical Outcomes Through Two Years in Major International Study; Achieves 10,000-patient Milestone PARIS--(BUSINESS WIRE)-- New clinical ...
Fierce Healthcare

Medtronic CoreValve® System Gains CE Mark for New Direct Aortic Approach to Transcatheter Aortic Valve Implantation

MINNEAPOLIS--(BUSINESS WIRE)-- Medtronic, Inc. (NYSE: MDT) today announced it has received CE (Conformité Européenne) Mark for the Medtronic CoreValve® System to be delivered using direct aortic ...
Nasdaq

Medtronic: 3-Year CoreValve Data Positive in High Risk Study

Medtronic plcMDT recently unveiled new three-year clinical outcomes from the high risk study of the CoreValve U.S. Pivotal Trial, at the 65th Annual Scientific Session & Expo of the American College ...
News Medical

U-M implants CoreValve Evolut R System in patients with severe aortic stenosis

The University of Michigan Frankel Cardiovascular Center is one of the first hospitals in the country to implant Medtronic's new investigational device during transcatheter aortic valve replacement ...
Nasdaq

Study Shows Medtronic's CoreValve TAVR Device Has Consistent And Cost Effective Performance

Medtronic, Inc. 's ( MDT) CoreValve transcatheter aortic valve replacement (TAVR) system continues to provide efficient treatment at two years for extreme-risk patients, the company announced at the ...